• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/1/21 2:35:18 PM ET
    $GWPH
    Major Pharmaceuticals
    Health Care
    Get the next $GWPH alert in real time by email
    SC 13G/A 1 gwph20a1.htm gwph20a1.htm - Generated by SEC Publisher for SEC Filing  

     

              CUSIP NO. 36197T103                    13G                               Page 1 of 14

     

     

                                                                                       UNITED STATES

                                                                  SECURITIES AND EXCHANGE COMMISSION

                                                                              Washington, D.C. 20549

     

                                                                                        SCHEDULE 13G

     

                                                           Under the Securities Exchange Act of 1934

                                                                                  (Amendment No. 1)*

     

                                                                              GW PHARMACEUTICALS PLC

                                                                                    (Name of Issuer)

     

                    American Depositary Shares, each representing 12 Ordinary Shares,p

                                        par value £0.001 per share1

                                                                      (Title of Class of Securities)

     

                                                                                           36197T103

     

                                                                                      (CUSIP Number)

     

                                                                                   December 31, 2020

                                             (Date of Event Which Requires Filing of this Statement)

     

              Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

              [X] Rule 13d‑1(b)

              [ ] Rule 13d‑1(c)

              [ ] Rule 13d‑1(d)

     

        *The remainder of this cover page shall be filled out for a reporting person's initial

        filing on this form with respect to the subject class of securities, and for any

        subsequent amendment containing information which would alter the disclosures provided in

        a prior cover page.

     

        The information required in the remainder of this cover page shall not be deemed to be

        "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or

        otherwise subject to the liabilities of that section of the Act but shall be subject to

        all other provisions of the Act (however, see the Notes).

     

     


    1  The title of the securities underlying the American Depository Shares is ordinary

      shares. The securities covered by this Schedule 13G may include ordinary shares and

      American Depository Shares. The CUSIP reported is the CUSIP for the American Depository

      Shares.

     


     
     

     

              CUSIP NO. 36197T103                    13G                               Page 2 of 14

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Franklin Resources, Inc.

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          Delaware

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

                          5.     SOLE VOTING POWER

     

                                       (See Item 4)

                          6.     SHARED VOTING POWER

     

                                       (See Item 4)

                          7.     SOLE DISPOSITIVE POWER

     

                                       (See Item 4)

                          8.     SHARED DISPOSITIVE POWER

     

                                       (See Item 4)

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                          23,080,308

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                           CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                           6.2%

     

              12.   TYPE OF REPORTING PERSON

     

                           HC, CO (See Item 4)

     


     
     

     

              CUSIP NO. 36197T103                    13G                               Page 3 of 14

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Charles B. Johnson

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          USA

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

                          5.    SOLE VOTING POWER

     

                                      (See Item 4)

     

                          6.    SHARED VOTING POWER

     

                                      (See Item 4)

     

                          7.    SOLE DISPOSITIVE POWER

     

                                      (See Item 4)

     

                          8.    SHARED DISPOSITIVE POWER

     

                                      (See Item 4)

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                          23,080,308

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          6.2%

     

              12.   TYPE OF REPORTING PERSON

     

                          HC, IN (See Item 4)

     


     
     

     

              CUSIP NO. 36197T103                    13G                               Page 4 of 14

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Rupert H. Johnson, Jr.

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          USA

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

                          5.    SOLE VOTING POWER

     

                                      (See Item 4)

     

                          6.    SHARED VOTING POWER

     

                                      (See Item 4)

     

                          7.    SOLE DISPOSITIVE POWER

     

                                      (See Item 4)

     

                          8.    SHARED DISPOSITIVE POWER

     

                                      (See Item 4)

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                          23,080,308

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          6.2%

     

              12.   TYPE OF REPORTING PERSON

     

                          HC, IN (See Item 4)

     


     
     

    CUSIP NO.    36197T103                           13G                            Page 5 of 14

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Franklin Advisers, Inc.

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          California

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

              5.    SOLE VOTING POWER

     

                          22,993,908

     

              6.    SHARED VOTING POWER

     

                          0

     

              7.    SOLE DISPOSITIVE POWER

     

                          22,993,908

     

              8.    SHARED DISPOSITIVE POWER

     

                          0

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                          22,993,908

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          6.1%

     

              12.   TYPE OF REPORTING PERSON

     

                          IA, CO (See Item 4)

             

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


     
     

    CUSIP NO.      36197T103                    13G                               Page 6 of 14

     

     

              Item 1.

     

              (a)   Name of Issuer

     

                          GW PHARMACEUTICALS PLC

     

              (b)   Address of Issuer's Principal Executive Offices

     

               Sovereign House, Vision Park

               Chivers Way, Histon

               Cambridge, CB24 9BZ

               United Kingdom

     

              Item 2.

     

              (a)   Name of Person Filing

                          (i):   Franklin Resources, Inc.

     

                          (ii):  Charles B. Johnson

     

                          (iii): Rupert H. Johnson, Jr.

     

                          (iv):  Franklin Advisers, Inc.

     

     

              (b)   Address of Principal Business Office or, if none, Residence

     

                          (i), (ii), and (iii):

                                      One Franklin Parkway

                                      San Mateo, CA 94403‑1906

                         (iv): One Franklin Parkway

                                      San Mateo, CA  94403‑1906

     

              (c)   Citizenship

     

                          (i):     Delaware

     

                          (ii) and (iii): USA

     

                          (iv): California

     

     

              (d)   Title of Class of Securities

     

                          American Depositary Shares, each representing 12 Ordinary Shares,

               par value £0.001 per share

     

              (e)   CUSIP Number

     

                          36197T103

     

     


     
     

              CUSIP NO. 36197T103                    13G                               Page 7 of 14

     

              Item 3.   If this statement is filed pursuant to §§240.13d‑1(b) or 240.13d‑2(b) or (c),

                                  check whether the person filing is a:

     

                            (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

                            (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

                            (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

                            (d) [ ] Investment company registered under section 8 of the Investment Company Act

                                            of 1940 (15 U.S.C 80a‑8).

     

                            (e) [X] An investment adviser in accordance with §240.13d‑1(b)(1)(ii)(E);

     

                            (f) [ ] An employee benefit plan or endowment fund in accordance with §240.13d‑1(b)

                                            (1)(ii)(F);

     

                            (g) [X] A parent holding company or control person in accordance with §240.13d‑1(b)

                                            (1)(ii)(G);

     

                            (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit

                                            Insurance Act (12 U.S.C. 1813);

     

                            (i) [ ] A church plan that is excluded from the definition of an investment company

                                            under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C.

                                            80a‑3);

                            (j) [ ] A non‑U.S. institution in accordance with §240.13d‑1(b)(ii)(J);

     

                            (k) [ ] Group, in accordance with §240.13d‑1(b)(1)(ii)(K).

     

                            If filing as a non‑U.S. institution in accordance with §240.13d‑1(b)(1)(ii)(J),

                            please specify the type of institution:

     

              Item 4.  Ownership

     

              The securities reported herein are beneficially owned by one or more open or closed end

         investment companies or other managed accounts that are investment management clients of

         investment managers that are direct and indirect subsidiaries (each, an “Investment

         Management Subsidiary” and, collectively, the “Investment Management Subsidiaries”) of

         Franklin Resources Inc. (“FRI”), including the Investment Management Subsidiaries listed

         in this Item 4.  When an investment management contract (including a sub advisory

         agreement) delegates to an Investment Management Subsidiary investment discretion or

         voting power over the securities held in the investment advisory accounts that are

         subject to that agreement, FRI treats the Investment Management Subsidiary as having sole

         investment discretion or voting authority, as the case may be, unless the agreement

         specifies otherwise. Accordingly, each Investment Management Subsidiary reports on

         Schedule 13G that it has sole investment discretion and voting authority over the

         securities covered by any such investment management agreement, unless otherwise noted in

         this Item 4.  As a result, for purposes of Rule 13d-3 under the Act, the Investment

         Management Subsidiaries listed in this Item 4 may be deemed to be the beneficial owners

         of the securities reported in this Schedule 13G.

     

         Beneficial ownership by Investment Management Subsidiaries and other FRI affiliates is

         being reported in conformity with the guidelines articulated by the SEC staff in Release

         No. 34-39538 (January 12, 1998) (the “1998 Release”) relating to organizations, such as

         FRI, where related entities exercise voting and investment powers over the securities

         being reported independently from each other.  The voting and investment powers held by

         each of FRI’s affiliates whose ownership of securities is disaggregated from that of FRI

         in accordance with the 1998 Release (“FRI Disaggregated Affiliates”) are exercised

         independently from FRI and from all other Investment Management Subsidiaries (FRI, its 

    affiliates and the Investment Management Subsidiaries other than FRI Disaggregated

         Affiliates are collectively, “FRI Aggregated Affiliates”). Furthermore, internal policies

         and procedures of, on the one hand, FRI Disaggregated Affiliates, and, on the other hand,

    FRI establish informational barriers that prevent the flow among, on the one hand, FRI

         Disaggregated Affiliates (including preventing the flow between such entities), and, on

         the other hand, the FRI Aggregated Affiliates of information that relates to the voting


     
     

              CUSIP NO. 36197T103                    13G                               Page 8 of 14

     

     

              and investment powers over the securities owned by their respective investment management

         clients.

     

         Consequently, FRI Disaggregated Affiliates report the securities over which they hold

    investment and voting power separately from the FRI Aggregated Affiliates for purposes

    of Section 13 of the Act.

     

              Charles B. Johnson and Rupert H. Johnson, Jr. (the “Principal Shareholders”) each own in

              excess of 10% of the outstanding common stock of FRI and are the principal stockholders

              of FRI.  FRI and the Principal Shareholders may be deemed to be, for purposes of Rule

              13d‑3 under the Act, the beneficial owners of securities held by persons and entities for

              whom or for which FRI subsidiaries provide investment management services.  The number of

              shares that may be deemed to be beneficially owned and the percentage of the class of

              which such shares are a part are reported in Items 9 and 11 of the cover pages for FRI

              and each of the Principal Shareholders.  FRI, the Principal Shareholders and each of the

              Investment Management Subsidiaries disclaim any pecuniary interest in any of such

              securities.  In addition, the filing of this Schedule 13G on behalf of the Principal

              Shareholders, FRI and the FRI Aggregated Affiliates, as applicable, should not be

         construed as an admission that any of them is, and each of them disclaims that it is, the

         beneficial owner, as defined in Rule 13d‑3, of any of the securities reported in this

         Schedule 13G.

     

              FRI, the Principal Shareholders, and each of the Investment Management Subsidiaries

              believe that they are not a “group” within the meaning of Rule 13d‑5 under the Act and

              that they are not otherwise required to attribute to each other the beneficial ownership

              of the securities held by any of them or by any persons or entities for whom or for which

              the Investment Management Subsidiaries provide investment management services.

     

                          (a)    Amount beneficially owned:

     

                                       23,080,308

     

                          (b)    Percent of class:

     

                                        6.2%

     

                          (c)    Number of shares as to which the person has:

     

                                  (i)   Sole power to vote or to direct the vote

     

                                              Franklin Resources, Inc.:                                         0

     

                                              Charles B. Johnson:                                               0

     

                                              Rupert H. Johnson, Jr.:                                           0

     

                                              Franklin Advisers, Inc.:                                 22,993,908

     

                                              Fiduciary Trust Company International:                       86,400

     

                                (ii)   Shared power to vote or to direct the vote

     

                                               0

     

                              (iii)   Sole power to dispose or to direct the disposition of

     

                                              Franklin Resources, Inc.:                                         0

     

                                              Charles B. Johnson:                                               0

     

                                              Rupert H. Johnson, Jr.:                                           0

     

     


     
     

     

              CUSIP NO. 36197T103                    13G                               Page 9 of 14

     

     

                                              Franklin Advisers, Inc.:                                 22,993,908

     

                                              Fiduciary Trust Company International:                       86,400

     

                                (iv)   Shared power to dispose or to direct the disposition of

     

                                               0

     

     

         Item 5.  Ownership of Five Percent or Less of a Class

     

                                If this statement is being filed to report the fact that as of the date hereof

                                the reporting person has ceased to be the beneficial owner of more than five

                                percent of the class of securities, check the following [ ]. 

     

              Item 6.  Ownership of More than Five Percent on Behalf of Another Person

     

                                 The clients of the Investment Management Subsidiaries, including investment

                                 companies registered under the Investment Company Act of 1940 and other managed

                                 accounts, have the right to receive or power to direct the receipt of dividends

                                 from, and the proceeds from the sale of, the securities reported herein.

     

              Item 7.  Identification and Classification of the Subsidiary Which Acquired the

                                Security Being Reported on By the Parent Holding Company

     

                                See Attached Exhibit C

     

              Item 8.  Identification and Classification of Members of the Group

     

                                Not Applicable

     

              Item 9.  Notice of Dissolution of Group

     

                                Not Applicable

     

     


     
     

     

              CUSIP NO. 36197T103                    13G                               Page 10 of 14

     

     

              Item 10. Certification

     

              By signing below I certify that, to the best of my knowledge and belief, the

              securities referred to above were acquired and are held in the ordinary course of

              business and were not acquired and are not held for the purpose of or with the

              effect of changing or influencing the control of the issuer of the securities and

              were not acquired and are not held in connection with or as a participant in any

              transaction having that purpose or effect, other than activities solely in connection

         with a nomination under § 240.14a-11.

     

              Exhibits

     

              Exhibit A ‑ Joint Filing Agreement

              Exhibit B ‑ Limited Powers of Attorney for Section 13 Reporting Obligations

         Exhibit C - Item 7 Identification and Classification of Subsidiaries

     

                                                                                      SIGNATURE

     

              After reasonable inquiry and to the best of my knowledge and belief, I certify that

              the information set forth in this statement is true, complete and correct.

     

              Dated:   January 25, 2021

     

              Franklin Resources, Inc.

     

              Charles B. Johnson

     

              Rupert H. Johnson, Jr.

     

              Franklin Advisers, Inc.

     

     

              By:     /s/VIRGINIA E. ROSAS

                             ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

                             Virginia E. Rosas

                             Assistant Secretary of Franklin Resources, Inc.

                             Attorney‑in‑Fact for Charles B. Johnson pursuant to Power of Attorney

                             attached to this Schedule 13G

     

                             Attorney‑in‑Fact for Rupert H. Johnson, Jr. pursuant to Power of Attorney

                             attached to this Schedule 13G

     

                Secretary of Franklin Advisers, Inc.

     

     

     


     
     

     

              CUSIP NO. 36197T103                    13G                               Page 11 of 14

     

              EXHIBIT A

     

              JOINT FILING AGREEMENT

     

              In accordance with Rule 13d‑1(k) under the Securities Exchange Act of 1934, as amended,

              the undersigned hereby agree to the joint filing with each other of the attached

              statement on Schedule 13G and to all amendments to such statement and that such

              statement and all amendments to such statement are made on behalf of each of them.

     

              IN WITNESS WHEREOF, the undersigned have executed this agreement on  January 25, 2021.

     

              Franklin Resources, Inc.

     

              Charles B. Johnson

     

              Rupert H. Johnson, Jr.

     

              Franklin Advisers, Inc.

     

     

              By:     /s/VIRGINIA E. ROSAS

                             ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

                             Virginia E. Rosas

                             Assistant Secretary of Franklin Resources, Inc.

                             Attorney‑in‑Fact for Charles B. Johnson pursuant to Power of Attorney

                             attached to this Schedule 13G

     

                             Attorney‑in‑Fact for Rupert H. Johnson, Jr. pursuant to Power of Attorney

                             attached to this Schedule 13G

     

                Secretary of Franklin Advisers, Inc.

     

     

     


     
     

              CUSIP NO. 36197T103                    13G                               Page 12 of 14

     

              EXHIBIT B

                                                         LIMITED POWER OF ATTORNEY

    FOR SECTION 13 AND 16 REPORTING OBLIGATIONS

     

              Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Alison E. Baur, Aliya S. Gordon, Steven J. Gray, Kimberly H. Novotny, Virginia E. Rosas, Navid J. Tofigh and Lori A. Weber each acting individually, as the undersigned’s true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

     

         1. prepare, execute, acknowledge, deliver and file Forms ID, Schedules 13D and 13G, and Forms 3, 4 and 5 (including any amendments thereto and any related documentation) with the United States Securities and Exchange Commission and any national securities exchanges relating to Franklin Resources, Inc. (“FRI”) and/or any registered closed-end company to which an affiliate of FRI is an investment adviser (each, a “Reporting Entity”), as considered necessary or advisable under Regulation S-T and Sections 13(d) and 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the “Exchange Act”); and

     

         2. seek or obtain, as the undersigned’s representative and on the undersigned’s behalf, information on transactions in the securities of any Reporting Entity from any person, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and

     

         3. perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

     

         The undersigned acknowledges that:

         1. this Limited Power of Attorney authorizes, but does not require, each such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information;

         2. any documents prepared and/or executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;

         3. none of FRI, any Reporting Entity nor any of such attorneys-in-fact assumes (i) any liability for the undersigned’s responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and

         4. this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned’s obligations under the Exchange Act, including without limitation, the reporting requirements under Section 16 of the Exchange Act.

     

         The undersigned hereby gives and grants each of the foregoing attorneys-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that each such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney, and indemnifies each of the foregoing attorneys-in-fact against any loss of any nature whatsoever arising in connection therewith.

         This Limited Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to each such attorney-in-fact.

         IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 8th day of April, 2020.

     

                                                                                                                                  /s/ Charles B. Johnson

                                                                                                                                  Signature

     

                                                                                                                                  Charles B. Johnson     

                                                                                                                                  Print Name


     
     

              CUSIP NO. 36197T103                    13G                               Page 13 of 14

     

              LIMITED POWER OF ATTORNEY

    FOR SECTION 13 AND 16 REPORTING OBLIGATIONS

     

         Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Alison E. Baur, Aliya S. Gordon, Steven J. Gray, Kimberly H. Novotny, Virginia E. Rosas, Navid J. Tofigh and Lori A. Weber each acting individually, as the undersigned’s true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

     

         1. prepare, execute, acknowledge, deliver and file Forms ID, Schedules 13D and 13G, and Forms 3, 4 and 5 (including any amendments thereto and any related documentation) with the United States Securities and Exchange Commission and any national securities exchanges relating to Franklin Resources, Inc. (“FRI”) and/or any registered closed-end company to which an affiliate of FRI is an investment adviser (each, a “Reporting Entity”), as considered necessary or advisable under Regulation S-T and Sections 13(d) and 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the “Exchange Act”); and

     

         2. seek or obtain, as the undersigned’s representative and on the undersigned’s behalf, information on transactions in the securities of any Reporting Entity from any person, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and

     

         3. perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

     

         The undersigned acknowledges that:

     

         1. this Limited Power of Attorney authorizes, but does not require, each such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information;

         2. any documents prepared and/or executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;

         3. none of FRI, any Reporting Entity nor any of such attorneys-in-fact assumes (i) any liability for the undersigned’s responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and

         4. this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned’s obligations under the Exchange Act, including without limitation, the reporting requirements under Section 16 of the Exchange Act.

     

         The undersigned hereby gives and grants each of the foregoing attorneys-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that each such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney, and indemnifies each of the foregoing attorneys-in-fact against any loss of any nature whatsoever arising in connection therewith.

         This Limited Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to each such attorney-in-fact.

         IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 8th day of April, 2020.

     

                                                                                                                            /s/ Rupert H. Johnson, Jr.

                                                                                                                            Signature

     

                                                                                                                            Rupert H. Johnson, Jr.   

                                                                                                                            Print Name


     
     

     

     

     

              CUSIP NO. 36197T103                    13G                               Page 14 of 14

     

     

              EXHIBIT C

     

              Franklin Advisers, Inc.                               Item 3 Classification: 3(e)

     

         Fiduciary Trust Company International                 Item 3 Classification: 3(b)

     

     

     

                 

     

    Get the next $GWPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GWPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GWPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

      Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm

      9/18/24 6:00:00 AM ET
      $IDYA
      $GWPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc

      DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (NASDAQ:JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines. "We are excited to welcome our GW colleagues to Jazz as we mark a transformative milestone in creating an innovative, high-growth, global biopharma leader in neuroscience with a worldwide commercial and operational footprint," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "The addition of GW further diversifies our commerical portfolio and innovative pipeline with therapies that are compl

      5/5/21 9:15:00 AM ET
      $JAZZ
      $GWPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen's Award for Enterprise in Innovation

      LONDON, April 29, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW", "the Company" or "the Group"), a world leader in discovering, developing and commercialising regulatory approved cannabis-based medicines, announces that it has received the Queen's Award for Enterprise 2021 in the Innovation category, recognising GW's innovative and ground-breaking work to harness cannabinoid science to create the world's first regulatory approved, prescription cannabis-based medicines. Since its inception in 1998, GW has successfully navigated significant barriers to enable the development, manufacture and commercialisation of regulatory approved cannabis-based medicines, leading the

      4/28/21 8:00:00 PM ET
      $GWPH
      Major Pharmaceuticals
      Health Care

    $GWPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James resumed coverage on GW Pharmaceuticals

      Raymond James resumed coverage of GW Pharmaceuticals with a rating of Hold

      2/22/21 7:29:26 AM ET
      $GWPH
      Major Pharmaceuticals
      Health Care
    • GW Pharmaceuticals downgraded by Citigroup

      Citigroup downgraded GW Pharmaceuticals from Buy to Neutral

      2/4/21 11:27:13 AM ET
      $GWPH
      Major Pharmaceuticals
      Health Care
    • GW Pharmaceuticals downgraded by HC Wainwright

      HC Wainwright downgraded GW Pharmaceuticals from Buy to Neutral

      2/4/21 7:30:03 AM ET
      $GWPH
      Major Pharmaceuticals
      Health Care

    $GWPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Tovey Christopher J. returned 2,496 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units

      4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)

      5/7/21 4:25:12 PM ET
      $GWPH
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Cline Darren S returned 5,556 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units

      4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)

      5/7/21 4:21:57 PM ET
      $GWPH
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by GRYSKA DAVID W

      4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)

      5/7/21 4:19:12 PM ET
      $GWPH
      Major Pharmaceuticals
      Health Care

    $GWPH
    SEC Filings

    See more
    • SEC Form 15-12B filed by GW Pharmaceuticals Plc

      15-12B - GW PHARMACEUTICALS PLC (0001351288) (Filer)

      5/17/21 6:09:29 AM ET
      $GWPH
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by GW Pharmaceuticals Plc

      S-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)

      5/5/21 5:27:52 PM ET
      $GWPH
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by GW Pharmaceuticals Plc

      S-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)

      5/5/21 5:26:02 PM ET
      $GWPH
      Major Pharmaceuticals
      Health Care

    $GWPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed

      SC 13G/A - GW PHARMACEUTICALS PLC (0001351288) (Subject)

      3/10/21 11:42:46 AM ET
      $GWPH
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - GW PHARMACEUTICALS PLC (0001351288) (Subject)

      2/16/21 3:58:07 PM ET
      $GWPH
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed

      SC 13G - GW PHARMACEUTICALS PLC (0001351288) (Subject)

      2/16/21 11:42:06 AM ET
      $GWPH
      Major Pharmaceuticals
      Health Care

    $GWPH
    Financials

    Live finance-specific insights

    See more
    • How An Ancient Medicine Is Taking On The $16 Trillion Pharmaceutical Industry

      LONDON, Dec. 3, 2020 /PRNewswire/ -- 2021 could be a big year for this soon-to-be $16-trillion biotech opportunity. More importantly, it could be a big year for companies pioneering a new form of therapy that could effectively treat the world's #1 disability. It's a disability that's costing the economy $1 trillion in lost production every single year. In fact, the revolutionary treatment could be at our doorstep by 2021. And the next few months are critical.   Mentioned in today's commentary includes:  Constellation Brands, Inc. (NYSE: STZ), Molson Coors Beverage Company (NYSE: TAP), Altria Group, Inc. (NYSE: MO), GW Pharmaceuticals plc (NASDAQ: GWPH), Curaleaf Holdings, Inc. (OTCQX: CUR

      12/3/20 9:00:00 AM ET
      $TAP
      $MO
      $JNJ
      $HEXO
      Beverages (Production/Distribution)
      Consumer Staples
      Medicinal Chemicals and Botanical Products
      Health Care

    $GWPH
    Leadership Updates

    Live Leadership Updates

    See more
    • IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

      Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm

      9/18/24 6:00:00 AM ET
      $IDYA
      $GWPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals